Hepatitis C Testing

Hepatitis C testing begins with a simple blood test, a draw or finger-prick, that looks for anti-HCV antibodies your immune system made in response to exposure. You can order this test online at a private lab (Quest, LabCorp) and walk in without an appointment, visit a health department, community health center, or STI clinic, or use an at-home kit that you mail to a CLIA-certified lab. Results return in 1–3 days. If the antibody test is reactive, a follow-up HCV RNA test is required to confirm whether you have an active current infection: antibodies persist for life, so a reactive result alone does not mean you currently have HCV. A provider or telehealth clinician will typically order the RNA test immediately on your behalf if your antibody result is reactive.

The timing depends on which test you use. HCV antibodies can appear as early as 6 weeks after exposure and are reliably detectable in most people by 8–11 weeks; a small minority take up to 6 months to seroconvert. For the most reliable antibody result, test at least 8–11 weeks after the most recent potential exposure. If you need an earlier answer, for example, after a needlestick injury or if your exposure was within the past 6 weeks, request an HCV RNA test, which can detect the virus as early as 1–2 weeks after exposure. A negative antibody result at 6 weeks is encouraging but not conclusive; confirm with a test at 12 weeks if your exposure was significant.

Not necessarily, and this is one of the most commonly misunderstood aspects of HCV testing. A reactive antibody test means your immune system was exposed to HCV at some point, but anti-HCV antibodies remain in your blood for life, even after you clear the virus spontaneously or are cured with treatment. The only way to determine whether you currently have active HCV infection is a follow-up HCV RNA test: if RNA is detectable, you have current infection and need treatment; if RNA is undetectable (negative), you either cleared the virus on your own or were previously cured. Never assume a reactive antibody means you currently have HCV, always get the confirmatory RNA test.

The USPSTF (2020) recommends HCV screening for all adults aged 18–79, regardless of risk factors, this is a Grade B recommendation covered with no out-of-pocket cost under most ACA-compliant plans. Beyond this universal recommendation, the following groups have elevated risk and should be screened more urgently or repeatedly: people who inject drugs (screen now and annually if exposure continues); people born between 1945 and 1965 (the 'baby boomer' cohort has approximately 3.5% prevalence); HIV-positive individuals (screen annually); people who received blood transfusions or organ transplants before July 1992; all pregnant people during each pregnancy; people on hemodialysis; and anyone with persistently elevated liver enzymes (ALT) on routine bloodwork.

The HCV antibody test typically costs $25–$90 self-pay at a private lab; at-home kits run approximately $45–$130. The USPSTF Grade B screening recommendation means HCV testing is covered at no out-of-pocket cost under most ACA-compliant plans. Health departments, syringe service programs, and harm-reduction organizations frequently offer free HCV antibody testing. If you are uninsured or underinsured, Medicaid covers HCV screening and treatment in all 50 states as of 2023. DAA treatment has high list prices but is rarely paid out of pocket: insurance, Medicaid, Medicare, and manufacturer patient assistance programs (PAPs) cover most patients.

Yes. At-home HCV testing kits use the same FDA-cleared antibody technology as in-clinic testing. You self-collect a blood sample via finger-prick, mail it to a CLIA-certified laboratory, and receive confidential results online within a few days. Cost is typically $45–$130. A reactive antibody result from an at-home kit must still be followed by a confirmatory HCV RNA test, which the kit service's medical team will typically arrange for you. At-home testing is a practical option for people who prefer privacy, have limited clinic access, or want to test between scheduled visits. It is not suitable for monitoring treatment response or confirming cure after treatment, those require in-person lab draws and provider oversight.

People born between 1945 and 1965, the 'baby boomer' generation, have HCV prevalence approximately 3.5 times higher than other adults, estimated at about 3.5% of this cohort. The elevated prevalence reflects two key historical factors: HCV circulated undetected in blood products and was spread through injection drug use in the 1960s to 1980s, before the virus was identified (in 1989) and before universal blood supply screening began (1992). Many people in this cohort acquired HCV decades ago through routes they may not have recognized as risks, have never been tested, and have been living with chronic infection for 30–40 years, accumulating significant liver damage silently. The CDC estimates that baby boomers account for approximately 75% of all HCV-related deaths in the U.S. Universal one-time screening of this cohort identifies infections that are still curable and can prevent HCC and liver failure.